Published in Blood Weekly, March 30th, 2006
Study 1: Valproic acid (VPA) was deemed clinically useful in low-risk myelodysplastic syndrome (MDS).
According to a study from Germany, "VPA inhibits historic deacetylase activity and induces differentiation of acute myeloid leukemia (AML) blasts in vitro. We observed clinical responses to VIA in patients with MDS and AML."
"Here, we report follow-up data on 75 patients. Of these, 66 were started on VPA monotherapy, with later addition of all-trans retinoic acid (ATRA) in patients who did not respond or relapsed. Nine patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.